Tryptamine Therapeutics (ENP)

Executive Summary

Tryptamine Therapeutics, now operating as Entropy Neurodynamics (ASX: ENP), is a clinical-stage Australian biotechnology company pioneering a patented intravenous (IV) infusion formulation of psilocin for psychedelic-assisted therapy. The company's precision dosing platform is designed to deliver consistent, controlled exposure to the active metabolite of psilocybin, aiming to improve therapeutic outcomes in neuropsychiatric and pain-related conditions. Its lead pipeline targets fibromyalgia, irritable bowel syndrome (IBS), binge-eating disorder, depression, chronic pain, and obsessive-compulsive disorder (OCD). The IV route offers potential advantages over oral administration by eliminating first-pass metabolism and allowing rapid onset and offset, which may enhance safety and efficacy in a clinical setting. As a public entity with a market cap of approximately AUD 15 million, the company is positioned in the emerging psychedelic therapeutics space, which has gained regulatory traction in Australia and globally. Despite early-stage clinical data, the unique IV delivery and focus on underserved indications differentiate it from peers. However, risks include small sample sizes, regulatory hurdles, and the need for larger trials to validate efficacy and safety.

Upcoming Catalysts (preview)

• Q1 2027Top-line Phase 1/2 trial results in fibromyalgia or IBS55% success
• Q4 2026Regulatory clearance for Phase 2 trials in binge-eating disorder70% success
• Q2 2027Strategic partnership or capital raising for Phase 2/3 development60% success